Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Lentiviral vectors for HSC gene therapy

Luigi Naldini • 7 Apr 2022
The 2022 Tandem Meetings
General

Luigi Naldini, MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milano, Italy, talks on the use of lentiviral vectors for hematopoietic stem cell (HSC) gene therapy, highlighting the benefits of autologous HSCs. Lentiviral vectors are used to treat a wide range of genetic diseases including primary immunodeficiencies, hemoglobinopathies, and metabolic storage disorders. Gene therapy using autologous HSCs enables patients to be treated with a milder conditioning regimen, with no risk of rejection or graft-versus-host disease (GvHD). This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Luigi Naldini

0:57
Advances in tools for genetic engineering of HSCs
Luigi Naldini • 7 Apr 2022
1:09
Reducing the toxicity of conditioning in HSC gene therapy
Luigi Naldini • 7 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals